Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer
Information source: Konkuk University Medical Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypothyroidism
Phase: N/A
Status: Recruiting
Sponsored by: Konkuk University Medical Center Official(s) and/or principal investigator(s): Suk Kyeong Kim, MD, PhD, Principal Investigator, Affiliation: Konkuk University Medical Center
Overall contact: Suk Kyeong Kim, MD, PhD, Phone: 82-2-2030-7531, Email: 20120137@kuh.ac.kr
Summary
1. The incidence of differentiated thyroid cancer is increasing in Korea. A significant
number of them experience severe hypothyroidism in preparation for radioactive iodine
(RAI) therapy after total thyroidectomy.
2. Because the function of thyroid hormone is closely linked with lipid and glucose
metabolism, overt hypothyroidism after thyroid hormone withdrawal during RAI therapy
may induce the changes of metabolic parameters.
3. We investigate the effects of thyroid hormone withdrawal on metabolic and
cardiovascular parameters during radioactive iodine therapy in differentiated thyroid
cancer.
Clinical Details
Official title: Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Changes of metabolic parameters
Secondary outcome: Changes of bone turnover markers
Detailed description:
1. Study design measurement of various parameters during hypothyroid state (before 1
month, the day and after 1 month of RAI therapy)
2. Measurements
1. Measurement of metabolic and cardiovascular parameters
- glucose profiles : HbA1c, fasting glucose level
- lipid profiles : free fatty acid, total, LDL-, HDL-, cholesterol,
triglyceride
- adipocytokines : retinol binding protein(RBP)
- 4, leptin, resistin, adiponectin
- markers of endothelial and cardiac function : high-sensitivity C-reactive
protein(hsCRP), homocystein, B-type natriuretic peptide(BNP)
- bone turnover markers : CTX, bone ALP
2. Scoring of symptoms and signs of hypothyroidism (Zulewski score)
- symptoms
- physical signs
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- radioiodine therapy after total thyroidectomy in differentiated thyroid cancer
- age over 18
Exclusion Criteria:
- kidney failure, liver failure, heart failure
- infection
- inflammation
- autoimmune disease
- other chronic disease
Locations and Contacts
Suk Kyeong Kim, MD, PhD, Phone: 82-2-2030-7531, Email: 20120137@kuh.ac.kr
Konkuk University Medical Center, Seoul 143-729, Korea, Republic of; Recruiting Jee Hyun An, Phone: 82-10-9089-4655, Email: jeehyunan@gmail.com Suk Kyoung Kim, MD, PhD, Principal Investigator Jee Hyun An, MD, PhD, Sub-Investigator Ki Ho Song, MD, PhD, Sub-Investigator Dong Lim Kim, MD, PhD, Sub-Investigator
Additional Information
Starting date: July 2012
Last updated: December 6, 2012
|